The genetics of hereditary common cancers

Current Opinion in Genetics and Development

Volumn 8, Issue 3, 1998, Pages 298-303

  De la Chapelle, Albert ^a,b   Peltomäki, Päivi ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BASE MISPAIRING; BREAST CANCER; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME 1; COLORECTAL CANCER; DNA REPAIR; FAMILIAL CANCER; GENETIC LINKAGE; HUMAN; MUTATION RATE; ONCOGENE; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0032102752     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(98)80085-3     Document Type: Article

References (42)

1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. of special interest Cell. 87:1996;159-170 A very insightful and comprehensive review.
2. Giardiello FM, Petersen GM, Piantadosi S, Gruber SB, Traboulsi EI, Offerhaus GJA, Muro K, Krush AJ, Booker SV, Luce MC, et al. APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis. Gut. 40:1997;521-525.
3. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell. 75:1993;631-639.
4. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM. The secretory phospholipase A2 gene is a candidate for the Mom 1 locus, a major modifier of Apc(Min)-induced intestinal neoplasia. Cell. 81:1995;957-966.
5. Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander E. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. of outstanding interest Nat Genet. 17:1997;88-91 Here, the proposed role of Pla2g2a as the substance responsible for Mom1-mediated resistance to intestinal tumor formation in mice is strongly supported. This experiment entailed the creation of a transgenic mouse through a cosmid injection into pronuclei. It may well be the first example of transgenic tumor prevention.
6. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54:1994;5523-5526.
7. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, Nakamura Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1:1992;229-233.
8. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat. 2:1993;425-434.
9. Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, Hamilton SR, Hampel H, Markowitz A, Klimstra D, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. of outstanding interest Nat Genet. 17:1997;79-83 This may well be the first example of a silent inherited polymorphism that creates a hypermutable region around itself. The data suggest a novel, indirect mechanism of cancer predisposition not resulting from the coding change caused by the sequence alteration.
10. Jass JR, Stewart SM. Evolution of hereditary non-polyposis colorectal cancer. Gut. 33:1992;783-786.
11. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri J, Boland CR. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 104:1993;1535-1549.
12. Peltomäki P, Vasen H. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology. 113:1997;1146-1158.
13. Wijnen J, Meera Khan P, Vasen H, van der Klift H, Mulder A, van Leeuwen-Cornelisse I, Bakker B, Losekoot M, Moller P, Fodde R. Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch repair gene mutations. Am J Hum Genet. 61:1997;329-335.
14. Nyström-Lahti M, Wu Y, Moisio A-L, Hofstra RMW, Osinga J, Mecklin J-P, Järvinen HJ, Leisti J, Buys CHCM, de la Chapelle A, Peltomäki P. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non-polyposis colorectal cancer. Hum Mol Genet. 5:1996;763-769.
15. Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchia A, Abe R, Yuasa Y. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 57:1997;3920-3923.
16. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet. 17:1997;271-272.
17. Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan K, Liedtke W, Cohen PE, Kane MF, Lipford JR, Yu N, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. of outstanding interest Cell. 91:1997;467-477 Mice homozygous for a knock-out of MSH6 have a cancer phenotype but not microsatellite instability in tumors possibly because MSH3 can partially compensate the deficient function of MSH6.
18. Peltomäki P, de la Chapelle A. Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res. 71:1997;93-119.
19. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Rüschoff J. Diagnostic microsatellite instability: definition, correlation with mismatch protein expression. Cancer Res. 57:1997;4749-4756.
20. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the MLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57:1997;808-811.
21. Hemminki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist A-M, Knuutila S, Salovaara R, Bodmer W, Shibata D, et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. of special interest Nat Genet. 15:1997;87-90 Hamartomatous polyps from a single patient were studied by comparative genomic hybridization and a suggestive loss of material from 19p was verified by a regular LOH study followed by genetic linkage analysis in families to pinpoint the locus for Peutz-Jeghers syndrome.
22. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Höglund P, et al. Germline mutations in a serine/threonine kinase gene in Peutz-Jeghers syndrome. of outstanding interest Nature. 391:1998;184-187 By positional cloning, the gene whose mutations cause Peutz-Jeghers syndrome was identified and found to encode a serine-threonine kinase.
23. Jenne DE, Reimann H, Nezu J-I, Friedel W, Loff S, Jeschke R, Müller O, Back W, Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. of outstanding interest Nat Genet. 18:1998;38-43 See annotation [22].
24. Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AMW, Hogervorst F, Brohet R, Ligtenberg MJL, Teugels E, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 60:1997;1041-1049.
25. Krainer M, Silva-Arrieta S, Fitzgerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. New Eng J Med. 336:1997;1416-1421.
26. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Eng J Med. 336:1997;1401-1408.
27. Burke W, Daly M, Garber J, Botkin J, Kahn MJE, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA. 277:1997;997-1003.
28. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New Eng J Med. 336:1997;1409-1415.
29. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH-F, Adey N, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations: risk factor analysis and implications for genetic testing. of special interest JAMA. 278:1997;1242-1250 A worldwide collaborative study emphasizing the practical aspect of BRCA1 mutation prevalence in a cohort of women judged to be at high risk of such a mutation; the figure of 12.5% is credible.
30. Breast Cancer Linkage Consortium Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 349:1997;1505-1510.
31. Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, Klausner RD. Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. Proc Natl Acad Sci USA. 94:1997;5820-5825.
32. Ishioka C, Suzuki T, Fitzgerald M, Krainer M, Shimodaira H, Shimada I, Nomizu T, Isselbacher KJ, Haber D, Kanamaru R. Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. Proc Natl Acad Sci USA. 94:1997;2449-2453.
33. Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. of outstanding interest Science. 274:1996;1371-1374 A genome-wide search of linkage for prostate cancer in a large number of families pinpointing a locus in chromosome 1 named HPC1. This is the first credible claim of a locus for prostate cancer susceptibility having been mapped.
34. Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE, Oesterling JE, Sandler HM, Lange K. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Ca Inst. 89:1997;955-959.
35. Cooney KA, Lange E, Wyszynski DF, Smith JR, Carpten JD, Trent JM, Bailey-Wilson JE. Linkage analysis in African-American prostate cancer families using 1q24-25 markers [abstract]. Am J Hum Genet. 61:1997;1583. (suppl).
36. McIndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, Li S, Gammack JT, Gay AA, Goode EL, et al. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet. 61:1997;347-353.
37. Eeles R, Durocher F, Edwards S, Teare D, Easton D, Dearnaley D, Shearer R, Ardern-Jones A, Dowe A, Badzioch M, et al. Does the hereditary prostate cancer gene, HPC1 contribute to a large proportion of familial prostate cancer? results from the CRC/BPG UK, Texan and Canadian Consortium [abstract]. Am J Hum Genet. 61:1997;345. (suppl).
38. Thibodeau SN, Wang Z, Tester DJ, French AJ, Schroeder JJ, Bissonet AS, Roberts SG, Blut ML, Schaid DJ, Smith JR, Trent JM. Linkage analysis at the HPC1 locus in hereditary prostate cancer families [abstract]. Am J Hum Genet. 61:1997;1733. (suppl).
39. Schleutker J, Matikainen M, Smith JR, Wyszynski DF, Pukkala E, Sankila R, Gillanders E, Freas-Lutz D, Pugh EW, Tilli E, et al. Search for founder effects: a genetic and epidemiologic study of hereditary prostate cancer in Finland [abstract]. Am J Hum Genet. 61:1997;1711. (suppl).
40. Grönberg H, Damber L, Damber J-E, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol. 146:1997;552-557.
41. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA. 94:1997;3320-3323.
42. Grönberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM, et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA. 278:1997;1251-1255.